Skip to content

Professor Klaus Pors,
Professor of Chemical Biology

Information about Professor Klaus Pors at the University of Bradford.

School of Pharmacy & Medical Sciences
(Faculty of Life Sciences)
+44 1274 236482
Photo of Professor Klaus Pors


Klaus Pors graduated with a BEng in Chemical Engineering from the University of Southern Denmark (Odense, Denmark) in 1998 and completed his studies in Medicinal Chemistry at the UCL School of Pharmacy in 2002. Both his PhD and Postdoc (UCL School of Pharmacy 2002-05) was focused on the discovery of anticancer agents and hypoxia-activated prodrugs to treat solid tumours. In 2005 he relocated to Bradford to take up a Yorkshire Cancer Research-funded lecturer and team leader position at the Institute of Cancer Therapeutics with focus on the discovery of tumour-selective therapies. He was promoted to Senior Lecturer in 2013 and to Professor of Chemical Biology in 2021.


Research in the Pors group is focussed on research at the interface between chemistry and biology. Traditional approaches to drug discovery such as target oriented synthesis and medicinal chemistry are used to develop focussed libraries of small molecules that are entirely new chemical entities or re-engineered versions of natural products. In addition, his group uses diversity-oriented synthesis to generate collections of small molecules of structural diverse architecture, which can be used to probe new chemical space or known biological pathways that are not well understood. In the context of cancer, novel therapeutics are designed to (i) exploit enzymatic and/or physiological conditions found unique to the tumour microenvironment or (ii) circumvent or exploit resistance mechanisms present in malignant tissue. Specific projects include:1) Development of tumour-selective prodrugs using bio-oxidative or bioreductive mode of activation.2) Development of aldehyde dehydrogenase (ALDH) inhibitors and prodrug derivatives.3) Development of aldo-keto reductase 1C3 (AKR1C3) inhibitors and prodrug derivatives.4) Development of antibody-drug conjugates (ADCs)In addition, our group is also interested in developing molecular fluorescent probes that can be used to stain fixed or live cells with wide applications in routine and research laboratories utilising flow cytometry and fluorescence imaging methods.Current research team include: Dr Sneha Swaroop (research fellow), postgraduate students Elisabet Battle, Zoë Jukes, Enric Arasanz Picher, Abdullahi Magaji Dauda, Enrica Denasio and Sam MacKenzie (intern student from York). Our research us supported by Breast Cancer Now, Secondary1st, The Schlumberger Foundation, Kidscan, ICT Doctoral Training Centre and University of Bradford (International Development Fund).


Details on teaching interests, highlights and modules are available for Professor Klaus Pors as follows:

Teaching interests

Cancer ResearchChemical BiologyDrug DiscoveryDrug MetabolismEnzymologyFluorophores for imaging and trackingHypoxiaMedicinal ChemistryStem Cells

Professional activities

Information about education, employment and areas of particular interest for Professor Klaus Pors is as follows:


  • UCL - PhD
  • University of Southern Denmark - BEng


There are 55 publications involving or that are attributed to Professor Klaus Pors. They are listed as:

  • peer reviewed journal (49)
  • reviews (6)

Peer Reviewed Journal

Professor Klaus Pors has 49 publication(s) listed under peer reviewed journal.
Title Year Publication name Journal Volume Pages Authors Editors ISSN Publisher DOI Location
Design and synthesis of a DNA-crosslinking azinomycin analogue 2005 Pors, Klaus; Casely-Hayford, M.A.; Hartley, J.A.; Patterson, Laurence H.; Searcey, M.
Genetic variation in the ADIPOQ gene and serum adiponectin increase the risk of bladder cancer. 2022 Journal of Applied Biomedicine 20 Elsalem L;Alfaqih MA;Al Bashir S;Halalsheh O;Basheer HA;Mhedat K;Khader Y;Pors K; 1214-0287 10.32725/jab.2022.012
In vitro radiosensitization of breast cancer with hypoxia-activated prodrugs. 2022 Journal of Cellular and Molecular Medicine 26 Aiyappa-Maudsley R;Elsalem L;Ibrahim AIM;Pors K;Martin SG; 1582-4934 10.1111/jcmm.17486
Expansion of the 4-(Diethylamino)benzaldehyde Scaffold to Explore the Impact on Aldehyde Dehydrogenase Activity and Antiproliferative Activity in Prostate Cancer 2022 Journal of Medicinal Chemistry 65 Ali I M Ibrahim, Elisabet Batlle, Smarakan Sneha, Rafael Jiménez, Raquel Pequerul, Xavier Parés, Till Rüngeler, Vibhu Jha, Tiziano Tuccinardi, Maria Sadiq, Fiona Frame, Norman J Maitland, Jaume Farrés, Klaus Pors 10.1021/acs.jmedchem.1c01367
The Chemerin-CMKLR1 Axis is Functionally important for Central Regulation of Energy Homeostasis 2022 Frontiers in Physiology 30 May 2022 Yun, H: Dumbell, R: Hanna, K: Bowen, J; McLean, SL; Kantamneni, S; Pors, K; Wu, QF; Helfer, G
New Aldo-Keto Reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold 2022 European Journal of Medicinal Chemistry 237 Agnese Chiara Pippione, Zühal Kilic-Kurt, Sandra Kovachka, Stefano Sainas, Barbara Rolando, Enrica Denasio, Klaus Pors, Salvatore Adinolfi, Daniele Zonari, Renzo Bagnati, Marco Lucio Lolli, Francesca Spyrakis, Simonetta Oliaro-Bosso1 and Donatella Boschi
Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer. 2021 Scientific Reports 11 Presa D;Khurram SA;Zubir AZA;Smarakan S;Cooper PA;Morais GR;Sadiq M;Sutherland M;Loadman PM;McCaul J;Shnyder SD;Patterson LH;Pors K; 2045-2322 10.1038/s41598-021-98217-z
Cytochrome P450 Binding and Bioactivation of Tumor-targeted Duocarmycin Agents. 2021 Drug Metabolism And Disposition: The Biological Fate Of Chemicals Bart AG;Morais G;Vangala VR;Loadman PM;Pors K;Scott EE; 1521-009X 10.1124/dmd.121.000642
Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies. 2021 Biomedicines 9 Sneha S;Baker SC;Green A;Storr S;Aiyappa R;Martin S;Pors K; 2227-9059 10.3390/biomedicines9030290
Design, Synthesis, Biological Evaluation and In Silico Study of Benzyloxybenzaldehyde Derivatives as Selective ALDH1A3 Inhibitors. 2021 Molecules 26 Ibrahim AIM;Ikhmais B;Batlle E;AbuHarb WK;Jha V;Jaradat KT;Jiménez R;Pequerul R;Parés X;Farrés J;Pors K; 1420-3049 10.3390/molecules26195770
How can the potential of the duocarmycins be unlocked for cancer therapy? 2021 Drug Discovery Today 26 Jukes Z;Morais GR;Loadman PM;Pors K; 1878-5832 10.1016/j.drudis.2020.11.020
Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds. 2021 Bioorganic and Medicinal Chemistry 40 Ortuzar N;Karu K;Presa D;Morais GR;Sheldrake HM;Shnyder SD;Barnieh FM;Loadman PM;Patterson LH;Pors K;Searcey M; 1464-3391 10.1016/j.bmc.2021.116167
Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid. 2018 European Journal of Medicinal Chemistry 150 Pippione AC;Carnovale IM;Bonanni D;Sini M;Goyal P;Marini E;Pors K;Adinolfi S;Zonari D;Festuccia C;Wahlgren WY;Friemann R;Bagnati R;Boschi D;Oliaro-Bosso S;Lolli ML
Aldehyde Dehydrogenases and Prostate Cancer: Shedding Light on Isoform Distribution to Reveal Druggable Target. 2020 Biomedicines 8 Quattrini L;Sadiq M;Petrarolo G;Maitland NJ;Frame FM;Pors K;La Motta C; 2227-9059 10.3390/biomedicines8120569
Multigram scale synthesis of polycyclic lactones and evaluation of antitumor and other biological properties. 2019 European Journal of Medicinal Chemistry 185 Grau L;Romero M;Privat-Contreras C;Presa D;Viñas M;Morral J;Pors K;Rubio-Martinez J;Pujol MD; 1768-3254 10.1016/j.ejmech.2019.111807
Current challenges and opportunities in treating hypoxic prostate tumors 2018 Journal of Cancer Metastasis and Treatment 4 McKenna DJ; Errington R; Pors K
Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention 2017 Journal of Cancer Metastasis and Treatment 3 Pippione AC; Boschi D; Pors K; Oliaro-Bosso S; Lolli ML OAE Publishing Inc
Expression and regulation of aldehyde dehydrogenases (ALDHs) in prostate cancer 2018 Journal of Cancer Metastasis and Treatment 4 Ibrahim AIM; Sadiq M; Frame F; Maitland NJ; Pors K 2454-2857 OAE Publishing Inc
Therapeutic antibodies against cancer stem cells: a promising approach. 2017 Cancer Immunology, Immunotherapy 66 Sneha S;Nagare RP;Priya SK;Sidhanth C;Pors K;Ganesan TS; 1432-0851 10.1007/s00262-017-2049-0
Synthesis and biological properties of aryl methyl sulfones. 2018 Bioorganic and Medicinal Chemistry 26 Navarro L;Rosell G;Sánchez S;Boixareu N;Pors K;Pouplana R;Campanera JM;Pujol MD; 1464-3391 10.1016/j.bmc.2018.06.038
Exploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo-keto reductase 1C3 target affinity 2019 MedChemComm 10 1476 - 1480 Santos A.;Sheldrake H.;Ibrahim A.;Danta C.;Bonanni D.;Daga M.;Oliaro-Bosso S.;Boschi D.;Lolli M.;Pors K. 2040-2503 10.1039/c9md00201d
Kinetic analysis of intracellular Hoechst 33342-DNA interactions by flow cytometry: Misinterpretation of side population status? 2013 Cytometry Part A 83 A 161 - 169 Smith P.;Wiltshire M.;Chappell S.;Cosentino L.;Burns P.;Pors K.;Errington R. 1552-4922 10.1002/cyto.a.22224
Minor structural modifications to alchemix influence mechanism of action and pharmacological activity 2012 Biochemical Pharmacology 83 1514 - 1522 Abdallah Q.;Phillips R.;Johansson F.;Helleday T.;Cosentino L.;Abdel-Rahman H.;Etzad J.;Wheelhouse R.;Kiakos K.;Bingham J.;Hartley J.;Patterson L.;Pors K. 0006-2952 10.1016/j.bcp.2012.02.017
Synthesis and biological evaluation of colchicine B-ring analogues tethered with halogenated benzyl moieties 2012 Journal of Medicinal Chemistry 55 11062 - 11066 Cosentino L.;Redondo-Horcajo M.;Zhao Y.;Santos A.;Chowdury K.;Vinader V.;Abdallah Q.;Abdel-Rahman H.;Fournier-Dit-Chabert J.;Shnyder S.;Loadman P.;Fang W.;Díaz J.;Barasoain I.;Burns P.;Pors K. 0022-2623 10.1021/jm301151t
Use of the hollow fiber assay for the evaluation of DNA damaging agents 2011 Journal of Pharmacological and Toxicological Methods 64 226 - 232 Veiga J.;Cooper P.;Pors K.;Patterson L.;Bibby M.;Shnyder S. 1056-8719 10.1016/j.vascn.2011.04.006
CYP2W1 polymorphism: Functional aspects and relation to risk for colorectal cancer 2013 Pharmacogenomics 14 1615 - 1622 Stenstedt K.;Travica S.;Guo J.;Barragan I.;Pors K.;Patterson L.;Edler D.;Mkrtchian S.;Johansson I.;Ingelman-Sundberg M. 1462-2416 10.2217/pgs.13.136
Synthesis and biological evaluation of colchicine C-ring analogues tethered with aliphatic linkers suitable for prodrug derivatisation 2012 Bioorganic and Medicinal Chemistry Letters 22 7693 - 7696 Fournier-Dit-Chabert J.;Vinader V.;Santos A.;Redondo-Horcajo M.;Dreneau A.;Basak R.;Cosentino L.;Marston G.;Abdel-Rahman H.;Loadman P.;Shnyder S.;Díaz J.;Barasoain I.;Falconer R.;Pors K. 0960-894X 10.1016/j.bmcl.2012.09.104
Probing cytochrome P450 bioactivation and fluorescent properties with morpholinyl-tethered anthraquinones 2018 Errington, R.J.; Sadiq, M.; Cosentino, L.; Wiltshire, M.; Sadiq, O.; Sini, Marcella; Lizano, E.; Pujol, M.D.; Ribeiro Morais, Goreti; Pors, Klaus
Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach 2017 Pippione, A.C.; Giraudo, A.; Bonanni, D.; Carnovale, I.M.; Marini, E.; Cena, C.; Costale, A.; Zonari, D.; Pors, Klaus; Sadiq, Maria; Boschi, D.; Oliaro-Bosso, S.; Lolli, M.L.
Mitoxantrone and Analogues Bind and Stabilize i-Motif Forming DNA Sequences 2016 Wright, E.P.; Day, H.A.; Ibrahim, Ali M.; Kumar, Jeethendra; Boswell, L.J.E.; Huguin, C.; Stevenson, C.E.M.; Pors, Klaus
Aldehyde dehydrogenases in cancer: an opportunity for biomarker and drug development? 2014 Pors, Klaus; Moreb, J.S.
Quantitative analysis of cytochrome P450 isoforms in human liver microsomes by the combination of proteomics and chemical probe-based assay 2014 Liu, X.; Hu, L.; Ge, G.; Yang, B.; Ning, J.; Sun, S.; Yang, L.; Pors, Klaus; Gu, J.
Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity 2013 Sheldrake, Helen M.; Travica, S.; Johansson, I.; Loadman, Paul M.; Sutherland, Mark H.; Elsalem, Lina M.I.; Illingworth, Nicola A.; Cresswell, Alexander J.; Reuillon, Tristan; Shnyder, Steven D.; Mkrtchian, S.; Searcey, M.; Ingelman-Sundberg, M.; Patterson, Laurence H.; Pors, Klaus
Solid-phase synthesis of duocarmycin analogues and the effect of C-terminal substitution on biological activity 2015 Stephenson, M.J.; Howell, L.A.; O'Connell, M.A.; Fox, K.R.; Adcock, C.; Kingston, J.; Sheldrake, Helen M.; Pors, Klaus; Collingwood, S.P.; Searcey, M.
Probing cytochrome P450-mediated activation with a truncated azinomycin analogue 2015 MedChemComm 6 187 - 191 Vinader, Victoria; Sadiq, Maria; Sutherland, Mark H.; Huang, M.Y.; Loadman, Paul M.; Elsalem, Lina M.I.; Shnyder, Steven D.; Cui, H.J.; Afarinkia, Kamyar; Searcey, M.; Patterson, Laurence H.; Pors, Klaus
The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53 2015 Thomas, A.; Perry, T.; Berhane, S.; Oldreive, C.; Zlatanou, A.; Williams, L.R.; Weston, V.J.; Stankovic, T.; Kearns, P.; Pors, Klaus; Grand, R.J.; Stewart, G.S.
Refining the chemical toolbox to be fit for educational and practical purpose for drug discovery in the 21st Century 2015 Lolli, M.L.; Narramore, S.; Fishwick, C.W.; Pors, Klaus
Rational development of novel activity probes for the analysis of human cytochromes P450 2016 ChemMedChem Sellars, J.D.; Skipsey, M.; Sadr-ul-Shaheed; Gravell, Sebastian; Abumansour, Hamza M.A.; Kashtl, Ghasaq; Irfan, Jawaria; Khot, Mohamed; Pors, Klaus; Patterson, Laurence H.; Sutton, Chris W.
The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow 2009 Drug Discovery Today 14 1045 - 1050 Pors, Klaus; Goldberg, F.W.; Leamon, C.P.; Rigby, A.C.; Snyder, S.A.; Falconer, Robert A.
Polysialic acid sustains cancer cell survival and migratory capacity in a hypoxic environment 2016 Scientific Reports 6 33026 Elkashef, Sara M.; Allison, Simon J.; Sadiq, Maria; Basheer, Haneen A.; Ribeiro Morais, Goreti; Loadman, Paul M.; Pors, Klaus; Falconer, Robert A. 10.1038/srep33026
Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins 2013 Travica, S.; Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Johansson, I.; Alandas, Mohammed N.; Sheldrake, Helen M.; Mkrtchian, S.; Patterson, Laurence H.; Ingelman-Sundberg, M.
Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder 2013 Sutherland, Mark H.; Gill, Jason H.; Loadman, Paul M.; Laye, Jonathan P.; Sheldrake, Helen M.; Illingworth, Nicola A.; Alandas, Mohammed N.; Cooper, Patricia A.; Searcey, M.; Pors, Klaus; Shnyder, Steven D.; Patterson, Laurence H.
Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity 2011 Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Sutherland, Mark H.; Sheldrake, Helen M.; Guino, M.; Kiakos, K.; Hartley, J.A.; Searcey, M.; Patterson, Laurence H.
Chemical and Biological Explorations of the Family of CC-1065 and the Duocarmycin Natural Products. 2009 Ghosh, Nandita; Sheldrake, Helen M.; Searcey, M.; Pors, Klaus
Synthesis of DNA-Directed Pyrrolidinyl and Piperidinyl Confined Alkylating Chloroalkylaminoanthraquinones: Potential for Development of Tumor-Selective N-Oxides 2006 Patterson, Laurence H.; Pors, Klaus; Shnyder, Steven D.; Teesdale-Spittle, P.H.; Hartley, J.A.; Searcey, M.; Zloh, M.
Alchemix: a novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer. 2003 Pors, Klaus; Paniwnyk, Z.; Teesdale-Spittle, P.H.; Plumb, J.A.; Willmore, E.; Austin, C.A.; Patterson, Laurence H.
Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells 2004 Pors, Klaus; Paniwnyk, Z.; Patterson, Laurence H.; Ruparelia, K.C.; Hartley, J.A.; Kelland, L.R.
Truncated azinomycin analogues intercalate into DNA. 2005 Casely-Hayford, M.A.; Pors, Klaus; Patterson, Laurence H.; Gerner, C.; Neidle, S.; Searcey, M.
Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells 2005 Teesdale-Spittle, P.H.; Pors, Klaus; Brown, R.; Patterson, Laurence H.; Plumb, J.A.


Professor Klaus Pors has 6 publication(s) listed under reviews.
Title Year Publication name Journal Volume Pages Authors Editors ISSN Publisher DOI Location
Aldehyde dehydrogenases in cancer: An opportunity for biomarker and drug development? 2014 Drug Discovery Today 19 1953 - 1963 Pors K.;Moreb J. 1359-6446 10.1016/j.drudis.2014.09.009
Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural products 2009 Current Topics in Medicinal Chemistry 9 1494 - 1524 Ghosh N.;Sheldrake H.;Searcey M.;Pors K. 1568-0266 10.2174/156802609789909812
Microtubule stabilising agents for cancer chemotherapy 2009 Expert Opinion on Therapeutic Patents 19 607 - 622 Zhao Y.;Fang W.;Pors K. 1354-3776 10.1517/13543770902775713
Therapeutic antibodies against cancer stem cells: a promising approach 2017 Cancer Immunology, Immunotherapy 66 1383 - 1398 Sneha S.;Nagare R.;Priya S.;Sidhanth C.;Pors K.;Ganesan T. 0340-7004 10.1007/s00262-017-2049-0
DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agents 2005 Current Topics in Medicinal Chemistry 5 1133 - 1149 Pors K.;Patterson L. 1568-0266 10.2174/156802605774370883
The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow 2009 Drug Discovery Today 14 1045 - 1050 Pors K.;Goldberg F.;Leamon C.;Rigby A.;Snyder S.;Falconer R. 1359-6446 10.1016/j.drudis.2009.07.004